Co-expression of somatostatin receptor subtypes and estrogen receptor-α mRNAs by non-functioning pituitary adenomas in young patients

Molecular and Cellular Endocrinology

Volumn 331, Issue 1, 2011, Pages 73-78

  Nishioka, Hiroshi ^a   Tamura, Kazuhiro ^b   Iida, Haruka ^b   Kutsukake, Masahiko ^b   Endo, Aiju ^b   Ikeda, Yukio ^a   Haraoka, Jo ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Dopamine receptor; Estrogen receptor; Non functioning pituitary adenomas; Somatostatin receptor (SSTR)

Indexed keywords

DOPAMINE 2 RECEPTOR; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; NON FUNCTIONING HYPOPHYSIS ADENOMA; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA; RECEPTORS, DOPAMINE; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; YOUNG ADULT;

EID: 78149409167     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.08.011     Document Type: Article

References (39)

1. Amagai Y., Ishikawa S., Gotoh T., Kayaba K., Nakamura Y., Kajii E. Age at menopause and mortality in Japan: the Jichi Medical School Cohort Study. J. Epidemiol. 2006, 16:161-166.
2. Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine 2003, 20:255-264.
3. Bevan J.S. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab. 2005, 90:1856-1863.
4. Chanson P., Brochier S. Non-functioning pituitary adenomas. J. Endocrinol. Invest. 2005, 28:93-99.
5. Colao A., Di Somma C., Pivonello R., Faggiano A., Lombardi G., Savastano S. Medical treatment for clinically non-functioning pituitary adenomas. Endocr. Relat. Cancer 2008, 15:905-915.
6. Colao A., Lombardi G., Annunziato L. Cabergoline. Expert Opin. Pharmacother. 2000, 1:555-574.
7. Daly A.F., Rixhon M., Adam C., Dempegioti A., Tichomirowa M.A., Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 2006, 91:4769-4775.
8. Florio T., Barbieri F., Spaziante R., Zona G., Hofland L.J., van Koetsveld P.M., Feelders R.A., Stalla G.K., Theodoropoulou M., Culler M.D., Dong J., Taylor J.E., Moreau J.-P., Saveanu A., Gunz G., Dufour H., Jaquet P. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenoma: a multi-center study. Endocr. Relat. Cancer 2008, 15:583-596.
9. Florio T., Thellung S., Arena S., Corsaro A., Spaziante R., Gussoni G., Acuto G., Giusti M., Giordano G., Schettini G. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur. J. Endocrinol. 1999, 141:396-408.
10. Greenman Y., Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J. Clin. Endocrinol. Metab. 1994, 78:398-403.
11. Greenman Y., Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J. Clin. Endocrinol. Metab. 1994, 79:724-729.
12. Greenman Y., Tordjman K., Osher E., Veshchev I., Shenkerman G., Reider-Groswasser I.I., Segev Y., Ouaknine G., Stern N. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin. Endocrinol. (Oxf.) 2005, 63:39-44.
13. Hu C., Yi C., Hao Z., Cao S., Li H., Shao X., Zhang J., Qiao T., Fan D. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol. Ther. 2004, 3:726-730.
14. Jaquet P., Ouafik L., Saveanu A., Gunz G., Fina F., Dufour H., Culler M.D., Moreau J.P., Enjalbert A. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J. Clin. Endocrinol. Metab. 1999, 84:3268-3276.
15. Katznelson L., Alexander J.M., Klibanski A. Clinically nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 1993, 76:1089-1094.
16. Kimura N., Tomizawa S., Arai K.N., Kimura N. Chronic treatment with estrogen up-regulates expression of sst2 messenger ribonucleic acid (mRNA) but down-regulates sst5 the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr. Relat. Cancer 2008, 15:583-596.
17. Kumar U., Grigorakis S.I., Watt H.L., Sasi R., Snell L., Watson P., Chaudhari S. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res. Treat. 2005, 92:175-186.
18. Lamberts S.W.J., Hofland L.C. Future treatment strategies of aggressive pituitary tumors. Pituitary 2008, 12:261-264.
19. Lloyd R.V., Jin L., Fields K., Kulig E. Effects of estrogens on pituitary cell and pituitary tumor growth. Pathol. Res. Pract. 1991, 187:584-586.
20. Miller G.M., Alexander J.K., Bikkal H.A., Katznelson L., Zervas N.T., Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 1995, 80:1386-1392.
21. Patel Y.C. Basic aspects of somatostatin receptors. Advances in Molecular and Cellular Endocrinology 1998, JAI Press, Greenwich, CT. D. LeRoich (Ed.).
22. Padova H., Rubinfeld H., Hadani M., Cohen Z.R., Nass D., Taylor J.E., Culler M.D., Shimon I. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas. Mol. Cell. Endocrinol. 2008, 286:214-218.
23. Pivonello R., Matrone C., Filippella M., Cavallo L.M., Di Somma C., Cappabianca P., Colao A., Annunziato L., Lombardi G. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J. Clin. Endocrinol. Metab. 2004, 89:1674-1683.
24. Ren S.G., Taylor J., Dong J., Yu R., Culler M.D., Melmed S. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J. Clin. Endocrinol. Metab. 2003, 88:4239-4245.
25. Renner U., Arzberger T., Pagotto U., Leimgrurber S., Uhl E., Muller A., Lange M., Weindl A., Stalla G.K. Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 1998, 83:1368-1375.
26. Rivero-Müller A., Chou Y.Y., Ji I., Lajic S., Hanyaloglu A.C., Jonas K., Rahman N., Ji T.H., Huhtaniemi I. Rescue of defective G protein-coupled receptor function in vivo by intermolecular cooperation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2319-2324.
27. Rocheville M., Lange D.C., Kumar U., Sasi R., Patel R.C., Patel Y.C. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 2000, 275:7862-7869.
28. Rocheville M., Lange D.C., Kumar U., Patel S.C., Patel R.C., Ratel Y.C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000, 288:154-157.
29. Schmid H.A. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol. Cell. Endocrinol. 2008, 286:69-74.
30. Sharma K., Patel Y.C., Srikant C.B. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol. Endocrinol. 1996, 10:1688-1696.
31. Shimon I. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine 2003, 20:265-269.
32. Strowski M.Z., Blake A.D. Function and expression of somatostatin receptors of the endocrine pancreas. Mol. Cell. Endocrinol. 2008, 286:169-179.
33. Taboada G.F., Luque R.M., Bastos W., Guimarães R.F., Marcondes J.B., Chimelli L.M., Fontes R., Mata P.J., Filho P.N., Carvalho D.P., Kineman R.D., Gadelha M.R. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur. J Endocrinol. 2007, 156:65-74.
34. Taboada G.F., Luque R.M., Neto L.V., de O Machado E., Sbaffi B., Domingues R.C., Marcondes J.B., Chimelli L.M.C., Fontes R., Niemeyer P., de Carvalho D.P., Kineman R.D., Gadelha M.R. Quantitative analysis in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur. J. Endocrinol. 2008, 158:295-303.
35. Turner H.E., Stratton I.M., Byrne J.V., Adams C.B., Wass J.A. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation-a follow-up study. Clin. Endocrinol. 1991, 51:281-284.
36. Visser-Wisselaar H.A., Van Uffelen C.J., Van Koetsveld P.M., Lichtenauer-Kaligis E.G., Waaijers A.M., Uitterlinden P., Mooy D.M., Lamberts S.W., Hofland L.J. 17-Beta-estradiol- dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. Endocrinology 1997, 138:1180-1189.
37. Xu Y., Song J., Berelowitz M., Bruno J.F. Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology 1996, 137:5634-5640.
38. Zafar M., Ezzat S., Ramyar L., Pan N., Smyth H.S., Asa S.L. Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J. Clin. Endocrinol. Metab. 1995, 80:3621-3627.
39. Zatelli M.C., Piccin D., Bottoni A., Ambrosio M.R., Margutti A., Padovani R., Scanarini M., Taylor J.E., Culler M.D., Cavazzini L., Degli Uberti E.C. Evidence of differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin A secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J. Clin. Endocrinol. Metab. 2004, 89:5181-5188.